The information highlighted (if any) are the most recent updates for this brand.
Each tablet contains Nicergoline 30 mg.
Pharmacology: Pharmacodynamics: Nicergoline, an ergoline derivative, has arteriolar vasodilating activity. Nicergoline acts by increasing cerebral blood circulation and consumption of oxygen and glucose. It appears to have effect on reducing the cerebrovascular resistance, enhancing catecholaminergic neurotransmitter function and inhibitory effect on platelet aggregation. Moreover, Nicergoline also promotes arterial vasodilation of the limbs by reducing vascular resistances. This can be helpful to correct abnormal blood flow in patients. The therapeutic dose has no effect to systemic arterial pressure.
Pharmacokinetics: Nicergoline is rapidly and almost completely absorbed after oral administration. The drug is metabolized by cytochrome P450 2D6 isozyme. Maximum plasma concentration occurs within 3 hours. More than 90% of the drug bound to human plasma protein (with high affinity for α1-acid glycoprotein). The major metabolites are 1-methyl-10-methoxy-dihydrolysergol (MMDL) and 10-methoxy-dihydrolysergol (MDL). Nicergoline has linear pharmacokinetics following oral administration. Approximately 70% of drug is excreted in urine.
For treatment the symptoms of acute or chronic, peripheral and cerebral vascular disorders listed as follows: Dementia associated with vascular dementia and Parkinson's disease, mental deterioration as follows such as cognitive, affective, and behavioral disturbances, impaired memory, mood depression; Chorio-retinal disorders; Balance disorders such as dizziness and vertigo; Tinnitus.
Orally 30 mg twice daily.
The drug should be taken on an empty stomach. The duration of treatment and dosage depends on response of patients.
If symptoms of overdosage occur, discontinue the drug and supportive treatment as needed.
Patients with hypersensitivity to Nicergoline or any components of the formulation.
Patients with myocardial infarction, acute bleeding, severe bradycardia, and postural hypotension.
Caution should be used in administering the drug in patients with hyperuricemia or with a history of gout and/or under treatment with drugs that might be able to interfere with the metabolism and excretion of uric acid.
Nicergoline may potentiate the hypotensive effect of antihypertensive agents. Use with caution when taking this drug with antihypertensive agents especially beta blockers.
Avoid concomitant use in patient with porphyria.
There is no adequate safety and efficacy information in pregnancy. Hence, use this product during pregnancy only if the potential benefit justifies the risk to the fetus.
There is no adequate safety and efficacy information in lactation. Therefore, nursing women should consider to discontinue nursing during this product use.
Central nervous system: Confusion, dizziness, insomnia, dry month, vertigo, headache, convulsion, irritability.
Cardiovascular system: Flushing.
Gastrointestinal: Gastrointestinal disturbances, hyperacidity, nausea, diarrhea, constipation.
Other: Hyperuricemia.
Nicergoline may potentiate the hypotensive effect of antihypertensive agents.
C04AE02 - nicergoline ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators.
Sergoline FC tab 30 mg
3 × 10's
Sign Out
